D
OptimizeRx Corporation
OPRX
$10.62
-$0.08-0.75%
D
Sell
3/28/2024Upgraded
OptimizeRx Corporation (OPRX) was upgraded to D- from E+ on 3/28/2024 due to an increase in the volatility index and valuation index.
OptimizeRx Corporation (OPRX) was upgraded to D- from E+ on 3/28/2024 due to an increase in the volatility index and valuation index.
E
Sell
3/13/2024Downgrade
OptimizeRx Corporation (OPRX) was downgraded to E+ from D- on 3/13/2024 due to a decline in the volatility index, growth index and valuation index.
OptimizeRx Corporation (OPRX) was downgraded to E+ from D- on 3/13/2024 due to a decline in the volatility index, growth index and valuation index.
D
Sell
1/9/2024Upgraded
OptimizeRx Corporation (OPRX) was upgraded to D- from E+ on 1/9/2024 due to a noticeable increase in the growth index, total return index and solvency index. Operating cash flow increased 162.18% from -$2.37M to $1.47M, EBIT increased 38.58% from -$4.88M to -$3M, and earnings per share increased from -$0.2449 to -$0.1722.
OptimizeRx Corporation (OPRX) was upgraded to D- from E+ on 1/9/2024 due to a noticeable increase in the growth index, total return index and solvency index. Operating cash flow increased 162.18% from -$2.37M to $1.47M, EBIT increased 38.58% from -$4.88M to -$3M, and earnings per share increased from -$0.2449 to -$0.1722.
E
Sell
11/6/2023Downgrade
OptimizeRx Corporation (OPRX) was downgraded to E+ from D- on 11/6/2023 due to a noticeable decline in the total return index, volatility index and solvency index.
OptimizeRx Corporation (OPRX) was downgraded to E+ from D- on 11/6/2023 due to a noticeable decline in the total return index, volatility index and solvency index.
D
Sell
5/19/2023Downgrade
OptimizeRx Corporation (OPRX) was downgraded to D- from D on 5/19/2023 due to a decline in the total return index, growth index and solvency index. Earnings per share declined from -$0.019 to -$0.3743, EBIT declined 717.22% from -$864.3 to -$7.06M, and operating cash flow declined 103.08% from $2.8M to -$86.3.
OptimizeRx Corporation (OPRX) was downgraded to D- from D on 5/19/2023 due to a decline in the total return index, growth index and solvency index. Earnings per share declined from -$0.019 to -$0.3743, EBIT declined 717.22% from -$864.3 to -$7.06M, and operating cash flow declined 103.08% from $2.8M to -$86.3.
D
Sell
5/31/2022Upgraded
OptimizeRx Corporation (OPRX) was upgraded to D from D- on 05/31/2022.
OptimizeRx Corporation (OPRX) was upgraded to D from D- on 05/31/2022.
D
Sell
5/13/2022Downgrade
OptimizeRx Corporation (OPRX) was downgraded to D- from D on 5/13/2022 due to a decline in the total return index and volatility index.
OptimizeRx Corporation (OPRX) was downgraded to D- from D on 5/13/2022 due to a decline in the total return index and volatility index.
D
Sell
5/10/2022Downgrade
OptimizeRx Corporation (OPRX) was downgraded to D from C- on 5/10/2022 due to a significant decline in the growth index, efficiency index and total return index. Earnings per share declined from $0.0266 to -$0.2104, net income declined 703.22% from $623.5 to -$3.76M, and EBIT declined 467.43% from $894 to -$3.28M.
OptimizeRx Corporation (OPRX) was downgraded to D from C- on 5/10/2022 due to a significant decline in the growth index, efficiency index and total return index. Earnings per share declined from $0.0266 to -$0.2104, net income declined 703.22% from $623.5 to -$3.76M, and EBIT declined 467.43% from $894 to -$3.28M.
C
Hold
3/4/2022Upgraded
OptimizeRx Corporation (OPRX) was upgraded to C- from D+ on 3/4/2022 due to a large increase in the growth index and valuation index. Earnings per share increased from $0.0022 to $0.0266, EBIT increased 68.65% from $530.1 to $894, and total revenue increased 25.97% from $16.13M to $20.31M.
OptimizeRx Corporation (OPRX) was upgraded to C- from D+ on 3/4/2022 due to a large increase in the growth index and valuation index. Earnings per share increased from $0.0022 to $0.0266, EBIT increased 68.65% from $530.1 to $894, and total revenue increased 25.97% from $16.13M to $20.31M.
D
Sell
1/14/2022Downgrade
OptimizeRx Corporation (OPRX) was downgraded to D+ from C- on 1/14/2022 due to a major decline in the total return index and volatility index.
OptimizeRx Corporation (OPRX) was downgraded to D+ from C- on 1/14/2022 due to a major decline in the total return index and volatility index.
C
Hold
11/30/2021Downgrade
OptimizeRx Corporation (OPRX) was downgraded to C- from C on 11/30/2021 due to a noticeable decline in the growth index and total return index. EBIT declined 93.99% from $635.8 to $38.2, and earnings per share declined from $0.02 to $0.0022.
OptimizeRx Corporation (OPRX) was downgraded to C- from C on 11/30/2021 due to a noticeable decline in the growth index and total return index. EBIT declined 93.99% from $635.8 to $38.2, and earnings per share declined from $0.02 to $0.0022.
C
Hold
8/6/2021Upgraded
OptimizeRx Corporation (OPRX) was upgraded to C from D on 8/6/2021 due to a significant increase in the growth index, efficiency index and solvency index. EBIT increased 332.47% from -$273.5 to $635.8, net income increased 155.24% from -$637.4 to $352.1, and earnings per share increased from -$0.04 to $0.02.
OptimizeRx Corporation (OPRX) was upgraded to C from D on 8/6/2021 due to a significant increase in the growth index, efficiency index and solvency index. EBIT increased 332.47% from -$273.5 to $635.8, net income increased 155.24% from -$637.4 to $352.1, and earnings per share increased from -$0.04 to $0.02.
D
Sell
11/10/2020Downgrade
OptimizeRx Corporation (OPRX) was downgraded to D from D+ on 11/10/2020 due to a major decline in the efficiency index.
OptimizeRx Corporation (OPRX) was downgraded to D from D+ on 11/10/2020 due to a major decline in the efficiency index.
D
Sell
10/9/2020Upgraded
OptimizeRx Corporation (OPRX) was upgraded to D+ from D on 10/9/2020 due to an increase in the total return index and volatility index.
OptimizeRx Corporation (OPRX) was upgraded to D+ from D on 10/9/2020 due to an increase in the total return index and volatility index.
D
Sell
9/24/2020Downgrade
OptimizeRx Corporation (OPRX) was downgraded to D from D+ on 9/24/2020 due to a decline in the total return index.
OptimizeRx Corporation (OPRX) was downgraded to D from D+ on 9/24/2020 due to a decline in the total return index.
D
Sell
9/9/2020Upgraded
OptimizeRx Corporation (OPRX) was upgraded to D+ from D on 9/9/2020 due to a noticeable increase in the total return index, growth index and efficiency index. Operating cash flow increased 103.41% from -$3.74M to $127.6, EBIT increased 59.68% from -$2.03M to -$819.2, and earnings per share increased from -$0.1509 to -$0.0735.
OptimizeRx Corporation (OPRX) was upgraded to D+ from D on 9/9/2020 due to a noticeable increase in the total return index, growth index and efficiency index. Operating cash flow increased 103.41% from -$3.74M to $127.6, EBIT increased 59.68% from -$2.03M to -$819.2, and earnings per share increased from -$0.1509 to -$0.0735.
D
Sell
11/6/2019Downgrade
OptimizeRx Corporation (OPRX) was downgraded to D from C- on 11/6/2019 due to a significant decline in the growth index, total return index and efficiency index. Operating cash flow declined 1,084.72% from -$81.8 to -$969.1, net income declined 486.35% from $406.6 to -$1.57M, and earnings per share declined from $0.03 to -$0.111.
OptimizeRx Corporation (OPRX) was downgraded to D from C- on 11/6/2019 due to a significant decline in the growth index, total return index and efficiency index. Operating cash flow declined 1,084.72% from -$81.8 to -$969.1, net income declined 486.35% from $406.6 to -$1.57M, and earnings per share declined from $0.03 to -$0.111.
C
Hold
10/23/2019Downgrade
OptimizeRx Corporation (OPRX) was downgraded to C- from C on 10/23/2019 due to a substantial decline in the total return index and efficiency index.
OptimizeRx Corporation (OPRX) was downgraded to C- from C on 10/23/2019 due to a substantial decline in the total return index and efficiency index.
C
Hold
7/22/2019Upgraded
OptimizeRx Corporation (OPRX) was upgraded to C from C- on 7/22/2019 due to a large increase in the total return index.
OptimizeRx Corporation (OPRX) was upgraded to C from C- on 7/22/2019 due to a large increase in the total return index.
C
Hold
5/16/2019Upgraded
OptimizeRx Corporation (OPRX) was upgraded to C- from D+ on 5/16/2019 due to a substantial increase in the total return index.
OptimizeRx Corporation (OPRX) was upgraded to C- from D+ on 5/16/2019 due to a substantial increase in the total return index.
D
Sell
5/9/2019Upgraded
OptimizeRx Corporation (OPRX) was upgraded to D+ from D on 5/9/2019 due to a noticeable increase in the growth index, efficiency index and total return index. Net income increased 105.91% from -$109.9 to $6.5, earnings per share increased from -$0.0096 to $0.0005, and total capital increased 8.84% from $18.46M to $20.09M.
OptimizeRx Corporation (OPRX) was upgraded to D+ from D on 5/9/2019 due to a noticeable increase in the growth index, efficiency index and total return index. Net income increased 105.91% from -$109.9 to $6.5, earnings per share increased from -$0.0096 to $0.0005, and total capital increased 8.84% from $18.46M to $20.09M.
D
Sell
3/29/2019Downgrade
OptimizeRx Corporation (OPRX) was downgraded to D from D+ on 3/29/2019 due to a large decline in the total return index, growth index and volatility index. Earnings per share declined from $0.02 to -$0.0096, and operating cash flow declined 13.53% from $1.08M to $932.8.
OptimizeRx Corporation (OPRX) was downgraded to D from D+ on 3/29/2019 due to a large decline in the total return index, growth index and volatility index. Earnings per share declined from $0.02 to -$0.0096, and operating cash flow declined 13.53% from $1.08M to $932.8.
D
Sell
12/24/2018Downgrade
OptimizeRx Corporation (OPRX) was downgraded to D+ from C- on 12/24/2018 due to a decline in the volatility index and total return index.
OptimizeRx Corporation (OPRX) was downgraded to D+ from C- on 12/24/2018 due to a decline in the volatility index and total return index.
C
Hold
12/13/2018Downgrade
OptimizeRx Corporation (OPRX) was downgraded to C- from C on 12/13/2018 due to a substantial decline in the total return index.
OptimizeRx Corporation (OPRX) was downgraded to C- from C on 12/13/2018 due to a substantial decline in the total return index.
C
Hold
11/19/2018Upgraded
OptimizeRx Corporation (OPRX) was upgraded to C from C- on 11/19/2018 due to a major increase in the total return index, efficiency index and volatility index. Total capital increased 8.89% from $15.8M to $17.2M.
OptimizeRx Corporation (OPRX) was upgraded to C from C- on 11/19/2018 due to a major increase in the total return index, efficiency index and volatility index. Total capital increased 8.89% from $15.8M to $17.2M.
C
Hold
5/11/2018Upgraded
OptimizeRx Corporation (OPRX) was upgraded to C- from D+ on 5/11/2018 due to a major increase in the growth index, solvency index and total return index. EBIT increased 48.16% from -$318.3 to -$165, the quick ratio increased from 2.41 to 3.34, and earnings per share increased from -$0.0081 to -$0.0064.
OptimizeRx Corporation (OPRX) was upgraded to C- from D+ on 5/11/2018 due to a major increase in the growth index, solvency index and total return index. EBIT increased 48.16% from -$318.3 to -$165, the quick ratio increased from 2.41 to 3.34, and earnings per share increased from -$0.0081 to -$0.0064.
D
Sell
11/29/2017Upgraded
OptimizeRx Corporation (OPRX) was upgraded to D+ from D on 11/29/2017 due to an increase in the total return index, solvency index and volatility index.
OptimizeRx Corporation (OPRX) was upgraded to D+ from D on 11/29/2017 due to an increase in the total return index, solvency index and volatility index.
D
Sell
11/3/2017Downgrade
OptimizeRx Corporation (OPRX) was downgraded to D from D+ on 11/3/2017 due to a decline in the growth index, efficiency index and solvency index. Operating cash flow declined 414.18% from $251.1 to -$788.9, EBIT declined 81.05% from -$347.8 to -$629.7, and earnings per share declined from -$0.0122 to -$0.0213.
OptimizeRx Corporation (OPRX) was downgraded to D from D+ on 11/3/2017 due to a decline in the growth index, efficiency index and solvency index. Operating cash flow declined 414.18% from $251.1 to -$788.9, EBIT declined 81.05% from -$347.8 to -$629.7, and earnings per share declined from -$0.0122 to -$0.0213.
D
Sell
10/24/2017Upgraded
OptimizeRx Corporation (OPRX) was upgraded to D+ from D on 10/24/2017 due to a substantial increase in the total return index, volatility index and growth index. Operating cash flow increased 227.33% from -$197.2 to $251.1, EBIT increased 59.61% from -$861.1 to -$347.8, and earnings per share increased from -$0.0297 to -$0.0122.
OptimizeRx Corporation (OPRX) was upgraded to D+ from D on 10/24/2017 due to a substantial increase in the total return index, volatility index and growth index. Operating cash flow increased 227.33% from -$197.2 to $251.1, EBIT increased 59.61% from -$861.1 to -$347.8, and earnings per share increased from -$0.0297 to -$0.0122.
D
Sell
3/16/2016Downgrade
OptimizeRx Corporation (OPRX) was downgraded to D from D+ on 3/16/2016 due to a substantial decline in the growth index, total return index and efficiency index. Net income declined 571.79% from $87.9 to -$414.7, EBIT declined 534.85% from $107.9 to -$469.2, and earnings per share declined from $0.0036 to -$0.0143.
OptimizeRx Corporation (OPRX) was downgraded to D from D+ on 3/16/2016 due to a substantial decline in the growth index, total return index and efficiency index. Net income declined 571.79% from $87.9 to -$414.7, EBIT declined 534.85% from $107.9 to -$469.2, and earnings per share declined from $0.0036 to -$0.0143.
D
Sell
3/11/2016Downgrade
OptimizeRx Corporation (OPRX) was downgraded to D+ from C- on 3/11/2016 due to a large decline in the volatility index and total return index.
OptimizeRx Corporation (OPRX) was downgraded to D+ from C- on 3/11/2016 due to a large decline in the volatility index and total return index.
C
Hold
1/12/2016Downgrade
OptimizeRx Corporation (OPRX) was downgraded to C- from C on 1/12/2016 due to a decline in the total return index.
OptimizeRx Corporation (OPRX) was downgraded to C- from C on 1/12/2016 due to a decline in the total return index.
C
Hold
12/28/2015Upgraded
OptimizeRx Corporation (OPRX) was upgraded to C from C- on 12/28/2015 due to a substantial increase in the total return index, solvency index and valuation index.
OptimizeRx Corporation (OPRX) was upgraded to C from C- on 12/28/2015 due to a substantial increase in the total return index, solvency index and valuation index.
C
Hold
11/13/2015Upgraded
OptimizeRx Corporation (OPRX) was upgraded to C- from D on 11/13/2015 due to a major increase in the growth index, efficiency index and total return index. Total capital increased 96.48% from $4.7M to $9.24M, operating cash flow increased 51.66% from $159.5 to $241.9, and total revenue increased 17.7% from $1.71M to $2.01M.
OptimizeRx Corporation (OPRX) was upgraded to C- from D on 11/13/2015 due to a major increase in the growth index, efficiency index and total return index. Total capital increased 96.48% from $4.7M to $9.24M, operating cash flow increased 51.66% from $159.5 to $241.9, and total revenue increased 17.7% from $1.71M to $2.01M.
D
Sell
8/21/2015Downgrade
OptimizeRx Corporation (OPRX) was downgraded to D from D+ on 8/21/2015 due to a decline in the solvency index, growth index and volatility index. The quick ratio declined from 2.44 to 2.44.
OptimizeRx Corporation (OPRX) was downgraded to D from D+ on 8/21/2015 due to a decline in the solvency index, growth index and volatility index. The quick ratio declined from 2.44 to 2.44.
D
Sell
7/31/2015Upgraded
OptimizeRx Corporation (OPRX) was upgraded to D+ from D on 7/31/2015 due to an increase in the volatility index and valuation index.
OptimizeRx Corporation (OPRX) was upgraded to D+ from D on 7/31/2015 due to an increase in the volatility index and valuation index.
D
Sell
7/16/2015Downgrade
OptimizeRx Corporation (OPRX) was downgraded to D from D+ on 7/16/2015 due to a noticeable decline in the total return index, solvency index and valuation index.
OptimizeRx Corporation (OPRX) was downgraded to D from D+ on 7/16/2015 due to a noticeable decline in the total return index, solvency index and valuation index.
D
Sell
3/12/2015Upgraded
OptimizeRx Corporation (OPRX) was upgraded to D+ from D on 3/12/2015 due to a noticeable increase in the solvency index, efficiency index and valuation index. Net income increased 648.2% from -$52.7 to -$394.3, and total capital increased 1.46% from $4.78M to $4.85M.
OptimizeRx Corporation (OPRX) was upgraded to D+ from D on 3/12/2015 due to a noticeable increase in the solvency index, efficiency index and valuation index. Net income increased 648.2% from -$52.7 to -$394.3, and total capital increased 1.46% from $4.78M to $4.85M.
D
Sell
8/15/2014Downgrade
OptimizeRx Corporation (OPRX) was downgraded to D from D+ on 8/15/2014 due to a major decline in the total return index, volatility index and efficiency index. Net income declined 91.93% from -$653.3 to -$52.7.
OptimizeRx Corporation (OPRX) was downgraded to D from D+ on 8/15/2014 due to a major decline in the total return index, volatility index and efficiency index. Net income declined 91.93% from -$653.3 to -$52.7.
D
Sell
5/19/2014Downgrade
OptimizeRx Corporation (OPRX) was downgraded to D+ from C on 5/19/2014 due to a substantial decline in the growth index, efficiency index and solvency index. Operating cash flow declined 72.67% from $829.6 to $226.7, and total revenue declined 27.25% from $1.81M to $1.32M.
OptimizeRx Corporation (OPRX) was downgraded to D+ from C on 5/19/2014 due to a substantial decline in the growth index, efficiency index and solvency index. Operating cash flow declined 72.67% from $829.6 to $226.7, and total revenue declined 27.25% from $1.81M to $1.32M.
NASDAQ
05/03/2024 4:00PM Eastern
Quotes delayed
